Vorolanib: Completed Ph II APEX Study enrollment

Tyrogenex completed enrollment of 157 patients previously treated with an anti-VEGF drug in the double-blind, placebo-controlled, international Phase II APEX Study evaluating 50, 100 and 200 mg oral v...